Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells

Jiang,Dan; Wang,Lingyao; Zhao,Tong; Zhang,Zhaoyu; Zhang,Renxia; Jin,Jingji; Cai,Yong; Wang,Fei

doi:10.3892/or.2016.5246

Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells

Authors:
- Dan Jiang
- Lingyao Wang
- Tong Zhao
- Zhaoyu Zhang
- Renxia Zhang
- Jingji Jin
- Yong Cai
- Fei Wang
View Affiliations

Affiliations: School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China
Published online on: November 15, 2016 https://doi.org/10.3892/or.2016.5246
Pages: 594-600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ganoderma lucidum polysaccharides (GLPs), isolated from spores, mycelia and fruiting bodies of Ganoderma lucidum, have been suggested to possess anticancer activities in a large number of basic studies. A recent survey revealed that GLP-induced inhibition of cancer cell growth was dependent on the existence of functional p53. However, the actual role of p53-mediated tumor-suppressing pathways in facilitating the anticancer effect of GLPs is still unclear. In the present study, we investigated the interaction between GLPs and mutant p53 that exists in more than half of the known types of cancers. Our results showed that GLPs reactivated mutant p53 in colorectal cancer HT29 (p53R273H) and SW480 (p53R273H&P309S) cells while applied alone or together with 5-fluorouracil (5-FU). This reactivation further induced cell growth inhibition and apoptosis. In addition, western blot assay and in vitro cell-free apoptosis assay suggested that the activation of mutant p53 was effective in both a transcriptional-dependent and -independent pathway. Altogether, our data demonstrated for the first time that GLPs show prominent anticancer activities by reactivating several types of mutant p53. Therefore, targeting mutant p53 by GLPs alongside other chemotherapeutics may be considered as a novel treatment strategy for cancer.

View Figures

View References

1	Wang XC, Xi RJ, Li Y, Wang DM and Yao YJ: The species identity of the widely cultivated Ganoderma, ‘G. lucidum’ (Ling-zhi), in China. PLoS One. 7:e408572012. View Article : Google Scholar
2	Li J, Zhang J, Chen H, Chen X, Lan J and Liu C: Complete mitochondrial genome of the medicinal mushroom Ganoderma lucidum. PLoS One. 8:e720382013. View Article : Google Scholar : PubMed/NCBI
3	Shiao MS: Natural products of the medicinal fungus Ganoderma lucidum: Occurrence, biological activities, and pharmacological functions. Chem Rec. 3:172–180. 2003. View Article : Google Scholar : PubMed/NCBI
4	Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP and Venook AP: And what other medications are you taking? J Clin Oncol. 29:e288–e291. 2011. View Article : Google Scholar : PubMed/NCBI
5	Papadopoulos I, Guo F, Lees S and Ridge M: An exploration of the meanings and experiences of cancer of Chinese people living and working in London. Eur J Cancer Care. 16:424–432. 2007. View Article : Google Scholar
6	Sliva D: Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther. 2:358–364. 2003. View Article : Google Scholar : PubMed/NCBI
7	Batra P, Sharma AK and Khajuria R: Probing Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (higher Basidiomycetes): A bitter mushroom with amazing health benefits. Int J Med Mushrooms. 15:127–143. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wachtel-Galor S, Yuen J, Buswell JA and Benzie IFF: Ganoderma lucidum (Lingzhi or Reishi): A Medicinal MushroomHerbal Medicine: Biomolecular and Clinical Aspects. Benzie IFF and Wachtel-Galor S: 92nd. CRC Press/Taylor & Francis; Boca Raton, FL: 2011, http://dx.doi.org/10.1201/b10787 View Article : Google Scholar
9	Xu Z, Chen X, Zhong Z, Chen L and Wang Y: Ganoderma lucidum polysaccharides: Immunomodulation and potential anti-tumor activities. Am J Chin Med. 39:15–27. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shang D, Li Y, Wang C, Wang X, Yu Z and Fu X: A novel polysaccharide from Se-enriched Ganoderma lucidum induces apoptosis of human breast cancer cells. Oncol Rep. 25:267–272. 2011.PubMed/NCBI
11	Huang CY, Chen JY, Wu JE, Pu YS, Liu GY, Pan MH, Huang YT, Huang AM, Hwang CC, Chung SJ, et al: Ling-Zhi polysaccharides potentiate cytotoxic effects of anticancer drugs against drug-resistant urothelial carcinoma cells. J Agric Food Chem. 58:8798–8805. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang J, Zhang L, Yu Y and Cheung PC: Enhancement of antitumor activities in sulfated and carboxymethylated polysaccharides of Ganoderma lucidum. J Agric Food Chem. 57:10565–10572. 2009. View Article : Google Scholar : PubMed/NCBI
13	Boh B: Ganoderma lucidum: A potential for biotechnological production of anti-cancer and immunomodulatory drugs. Recent Patents Anticancer Drug Discov. 8:255–287. 2013. View Article : Google Scholar
14	Jin X, Beguerie J Ruiz, Sze DM and Chan GC: Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 6:CD0077312012.
15	Zhang J, Chen JM, Wang XX, Xia YM, Cui SW, Li J and Ding ZY: Inhibitor or promoter? The performance of polysaccharides from Ganoderma lucidum on human tumor cells with different p53 statuses. Food Funct. 7:1872–1875. 2016. View Article : Google Scholar : PubMed/NCBI
16	Liang Z, Guo YT, Yi YJ, Wang RC, Hu QL and Xiong XY: Ganoderma lucidum polysaccharides target a Fas/caspase dependent pathway to induce apoptosis in human colon cancer cells. Asian Pac J Cancer Prev. 15:3981–3986. 2014. View Article : Google Scholar : PubMed/NCBI
17	Liu Y and Bodmer WF: Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA. 103:976–981. 2006. View Article : Google Scholar : PubMed/NCBI
18	Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:705–708. 1989. View Article : Google Scholar : PubMed/NCBI
19	Hainaut P and Hollstein M: p53 and human cancer: The first ten thousand mutations. Adv Cancer Res. 77:81–137. 2000. View Article : Google Scholar : PubMed/NCBI
20	Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM: p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
22	Moll UM, Wolff S, Speidel D and Deppert W: Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol. 17:631–636. 2005. View Article : Google Scholar : PubMed/NCBI
23	Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 303:1010–1014. 2004. View Article : Google Scholar : PubMed/NCBI
24	Chipuk JE and Green DR: Cytoplasmic p53: Bax and forward. Cell Cycle. 3:429–431. 2004. View Article : Google Scholar : PubMed/NCBI
25	Boh B, Berovic M, Zhang J and Zhi-Bin L: Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 13:265–301. 2007. View Article : Google Scholar : PubMed/NCBI
26	Chen Y, Xie MY, Wang YX, Nie SP and Li C: Analysis of the monosaccharide composition of purified polysaccharides in Ganoderma atrum by capillary gas chromatography. Phytochem Anal. 20:503–510. 2009. View Article : Google Scholar : PubMed/NCBI
27	Lin ZB: Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci. 99:144–153. 2005. View Article : Google Scholar : PubMed/NCBI
28	Li N, Hu YL, He CX, Hu CJ, Zhou J, Tang GP and Gao JQ: Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. J Pharm Pharmacol. 62:139–144. 2010. View Article : Google Scholar : PubMed/NCBI
29	Vousden KH and Prives C: Blinded by the light: The growing complexity of p53. Cell. 137:413–431. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499:214–218. 2013. View Article : Google Scholar : PubMed/NCBI
31	Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
32	Wang F, Liu J, Robbins D, Morris K, Sit A, Liu YY and Zhao Y: Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis. 16:301–310. 2011. View Article : Google Scholar : PubMed/NCBI
33	Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J and Fersht AR: Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41:6034–6044. 2013. View Article : Google Scholar : PubMed/NCBI
34	Selivanova G and Wiman KG: Reactivation of mutant p53: Molecular mechanisms and therapeutic potential. Oncogene. 26:2243–2254. 2007. View Article : Google Scholar : PubMed/NCBI